Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784479 | 1.00 | CCR2 (0.57) | CCR2AKR1B1PTGS2POLBALDH1A1 | |
| SCHEMBL5097716 | 0.82 | CCR2 (0.49) | CCR2PTGS2CES2CES1ADRA2A | |
| SCHEMBL24805970 | 0.81 | CCR2 (0.44) | CCR2AKR1B1PTGS2POLBALDH1A1 | |
| SCHEMBL778076 | 0.81 | AKR1B1 (0.58) | CCR2AKR1B1POLBALDH1A1MAPT | |
| SCHEMBL11995566 | 0.80 | PTGS2 (0.46) | CCR2PTGS2ALDH1A1L3MBTL1PTGS1 | |
| SCHEMBL3604890 | 0.80 | CCR2 (0.44) | CCR2PTGS2ALDH1A1L3MBTL1 | |
| SCHEMBL4572915 | 0.80 | L3MBTL1 (0.59) | CCR2PTGS2ALDH1A1L3MBTL1ADRA2A | |
| SCHEMBL11162849 | 0.79 | AKR1B1 (0.47) | CCR2AKR1B1POLBALDH1A1MAPT | |
| Methane SCHEMBL5104887 | 0.79 | AKR1B1 (0.56) | CCR2AKR1B1POLBALDH1A1MAPT | |
| SCHEMBL1581645 | 0.78 | NMT1 (0.49) | CCR2AKR1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2019147783-A1 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| US-7122680-B2 | 3-Substituted oxindole β3 agonsists | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-10-20 | — | — | US | disclosed |
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | JESUDASON CYNTHIA DARSHINI (US) | 2005-03-10 | — | — | US | disclosed |
| US-6825220-B2 | INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ELI LILLY AND COMPANY | 2004-05-20 | — | — | US | disclosed |
| WO-2004011457-A1 | 1-PHENYLPIPERIDIN-3-ONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | CCR2 83/4885AKR1B1 2094/4885PTGS2 465/4885 |
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | CCR2 133/4885AKR1B1 666/4885PTGS2 2820/4885 |
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | CCR2 334/4885AKR1B1 381/4885PTGS2 1586/4885 |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | CCR2 2824/4885AKR1B1 144/4885PTGS2 1026/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | CCR2 4415/4885AKR1B1 250/4885PTGS2 2664/4885 |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | CTRL, PRCP, CLPP | CCR2 1865/4885AKR1B1 2841/4885PTGS2 954/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | CCR2 1022/4885AKR1B1 1251/4885PTGS2 1234/4885 |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ADRB3, ADRB2, ADRB1 | CCR2 288/4885AKR1B1 244/4885PTGS2 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.